Subscriber Content Preview | Request a free trialSearch  


Third Point tells Amgen: Break it up

Amgen plans to expound on plans for the company at its Oct. 28 investor meeting. Continue reading

AbbVie backs away from Shire takeover after tax changes

The Dublin target insists the deal should go ahead and notes that it's in line for a $1.635 billion breakup fee if it collapses. Continue reading

Rural Metro award could have far-reaching effects

The $76M judgment was one of the largest in the history of the Court of Chancery. Continue reading

Working on the A[ctivist]-Team

Dissidents find teaming up helps cover costs and drive insurgencies at larger companies. But the members of the group must stay on the same page and share the same goals if a target agrees to sell itself. Continue reading

Steris chases tax cuts with Synergy Health purchase

The Ohio company defies a regulatory clampdown on inversions with the $1.9 billion deal. Continue reading

Changing hospital dynamic leads BD to buy CareFusion

Cash, stock $12.2 billion deal would solidify BD position in infection control, respiratory care. Continue reading

Salix seen as target after scrapping Cosmo purchase

The N.C. drugmaker cites the "changed political environment" for its decision to back out of a tax inversion deal to buy the Italian company. Continue reading

Del. Supreme court overturns jury in merger case

A lower court failed to distinguish between LOI terms superseded by merger contract and those not. Continue reading

Don't swallow that poison pill! Use a buyout shop instead

Companies under siege from activists may turn to private equity firms as 'white squires.' Playing such a role represents a potentially profitable new business opportunity, but it also cuts against the buyout industry's traditionally collaborative approach. Continue reading

Treasury takes small steps to rein in inversions

The measure does little to change tax rules as the Obama administration disavows desire to bar the move outright. Continue reading

Belize brokers arrested after 2-year FBI stock manipulation probe

The brokers have been tied to numerous suspected pump and dumps of U.S. stocks. Continue reading

Siga seeks bankruptcy shelter

The biological warfare defense company files for Chapter 11 because of a pending judgment that could total $232 million. Continue reading

Meet the journalists

Pamela Taulbee

Senior Writer: Healthcare

Jim Cramer's 2013 M&A predictions

The Founder of and host of Mad Money makes his predictio ... Video

More Healthcare video

The Deal's Webcast Series

If you have not had the chance to enjoy our Webcast Series, now is the time. Join these free 60-minute discussions and get a handle on the latest strategies and tactics in private equity, cross-border and middle market dealmaking and more.

Industry Events

View information on all upcoming industry events which The Deal representatives are participating in.

The Deal Economy Event

The Deal’s senior journalists host the industry's leading M&A forecasting event, an invitation-only gathering of influential members of the deal community discussing the outlook for dealmaking in the coming year.

The Deal on Twitter

Follow @TheDealNewsroom for the latest news across mergers and acquisitions, auctions, financings, restructurings and more!